Results 81 to 90 of about 18,746 (183)
Brain and Behavior, Volume 16, Issue 2, February 2026.Donepezil research in cognitive impairment: a bibliometric and scientometric analysis. ABSTRACT Background Cognitive impairment (CI) greatly affects global health and quality of life. Donepezil, a widely used treatment for CI, particularly in Alzheimer's disease, has been extensively studied; however, a comprehensive bibliometric analysis summarizing ...
Wencai Wang +5 more
wiley +1 more source
Neuropsychiatric Disease and Treatment, 2008 Haris Carageorgiou1, Antonios C Sideris1, Ioanna Messari1, Chrissoula I Liakou1, Stylianos Tsakiris21Department of Pharmacology, 2Department of Physiology, Medical School, University of Athens, Athens, GreeceAbstract: We investigated the effects of ...
Haris Carageorgiou +4 more
doaj
Rivastigmine effects on EEG spectra and three-dimensional LORETA functional imaging in Alzheimer's disease [PDF]
, 2018 Objective: The objective of the study is to investigate the electrocortical and the global cognitive effects of 3months rivastigmine medication in a group of mild to moderate Alzheimer's disease patients.
Faber, Pascal +6 more
core
MedComm, Volume 7, Issue 2, February 2026.Neurons, immune cells, and other cellular components within the disease microenvironment (such as stromal cells and tumor cells) constitute a dynamically evolving ecosystem. Neurons directly modulate immune cell activity and inflammatory responses through the release of neurotransmitters (e.g., norepinephrine and CGRP), while also promoting tumor ...
Xin Guo +11 more
wiley +1 more source
Gait and cognition: mapping the global and discrete relationships in ageing and neurodegenerative disease [PDF]
, 2016 Recent research highlights the association of gait and cognition in older adults but a stronger understanding is needed to discern coincident pathophysiology, patterns of change, examine underlying mechanisms and aid diagnosis.
Bunce, Jennifer +4 more
core +2 more sources
Insights into (S)-rivastigmine inhibition of butyrylcholinesterase (BuChE): Molecular docking and saturation transfer difference NMR (STD-NMR) [PDF]
, 2016 Rivastigmine is a very important drug prescribed for the treatment of Alzheimer's disease (AD) symptoms. It is a dual inhibitor, in that it inhibits both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE).
Bacalhau, P +3 more
core +1 more source
Rivastigmine in Chinese patients with subcortical vascular dementia
Neuropsychiatric Disease and Treatment, 2007 Vincent Mok1, Adrian Wong1, Simon Ho2, Thomas Leung1, Wynnie WM Lam2, Ka Sing Wong11Department of Medicine and Therapeutics; 2Department of Radiology and Organ Imaging, The Chinese University of Hong Kong, Shatin, Hong Kong, ChinaBackground: We explored ...
Vincent Mok +5 more
doaj
A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementia [PDF]
, 2013 AIMS: The 24-week, prospective, randomized, double-blind ACTION study investigated the efficacy, safety, and tolerability of 13.3 versus 4.6 mg/24 h rivastigmine patch in patients with severe Alzheimer's disease (AD).
Farlow, Martin R. +4 more
core +2 more sources
Acta Medica Iranica, 2008 Alzheimer's disease is the most common degenerative disease of brain. Nowadays, the most common treatment being used to slow down disease progression, include Donepezil , Rivastigmine and Galantamine, which all of them act as inhibitors of acetyl ...
R. Abolfazli +1 more
doaj
Effects of non-pharmacological or pharmacological interventions on cognition and brain plasticity of aging individuals. [PDF]
, 2014 Brain aging and aging-related neurodegenerative disorders are major health challenges faced by modern societies. Brain aging is associated with cognitive and functional decline and represents the favourable background for the onset and development of ...
Cesinaro, Stefano +4 more
core +2 more sources